Notícias e Atividades da Clal Biotechnology Industries

A Clal Biotechnology Industries pertence à AAR Consortium. AAR Consortium tem presença direta em 13 países.

AAR Consortium possui 49 subsidiárias incluindo Access Industries, ADA Worldwide e Alfa Bank.

Eles estão dentro:

• Música34%
• Mídia16%
• Outro50%

Veja o organograma con seus 6 executivos principais

Biografias mais buscadas da Clal Biotechnology Industries

• Avi Fischer, Chairman of the Board and Chief Executive Officer
• Gabi Barabash, Director
• Bazil Gamzu, Director

Criar um alerta
para seguir os movimentos de executivos da Clal Biotechnology Industries.

AAR Consortium possui 2.431 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• AdvanCell acaba de anunciar uma arrecadação de fundos de 315 milhões de dólares. (publicado em 21 de julho de 2026).
• Allotera Therapeutics acaba de anunciar uma arrecadação de fundos de 35 milhões de dólares. (publicado em 21 de julho de 2026).
• Draig Therapeutics acaba de anunciar uma arrecadação de fundos de 65 milhões de dólares. (publicado em 21 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Clal Biotechnology Industries

• אסיפת בעלי מניות 31.10.2024 14:00 – CBI
• MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | MediWound
• MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers | MediWound
• Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Investors – Gamida Cell Ltd.
• BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization | BioLineRx
• BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition | BioLineRx
• Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
• View more press releases Close

Redes sociais sobre Clal Biotechnology Industries

• Clal Biotechnology Industries na Wikipedia, Google News e Yahoo Finance
• Clal Biotechnology Industries na LinkedIn, X (Twitter) e YouTube